CD79B and non-Hodgkin lymphoma: Thus, this study aimed to evaluate the efficacy of polatuzumab vedotin as a CD79B gene-targeting drug across different subgroups of Non-Hodgkin Lymphoma patients by adopting a systematic review and meta-analysis research approach.